| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_def4b65d4bc6a6aa00d10409e9993fba |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 |
| filingDate |
2022-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb5998d37d0a761d371c0317aeb4a739
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d6385435aff7937fc28dec56a303d1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07e33b03d18905fc5e0dd603b9845566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c611c4211c2c428368925a5b1408af3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c16d5eef010dabbcf90a420b367dcecd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6559126d168783d973b58f4629c4a6e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b142e4101de15187512e8474c2cd6ee2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb5d412e792624c4a9247fafcc2e5464
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2de3a5ba6c53b33b88ccf7e65715814f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8819dc9ba62661973cf93c73ca05501
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20ad807c011a64f19698bc445cf734b8 |
| publicationDate |
2023-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2023001890-A2 |
| titleOfInvention |
Budesonide 21-phosphate sodium salt for use as anti-inflammatory or anti-asthmatic agent |
| abstract |
The present invention relates to budesonide 21 -phosphate sodium salt for use as anti-inflammatory agent or as anti-asthmatic agent. The invention further relates to pharmaceutical compositions containing the same. |
| priorityDate |
2021-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |